The outlook of companies tied to Sildenafil's past presents a intricate investment scenario . While the initial surge generated substantial gains, generic copies have significantly eroded market share . Investing in connected pharmaceutical companies now requires a discerning assessment of intellectual property here safeguards, evolving healthcare